Advertisement

Search Results

Advertisement



Your search for all items matches 22617 pages

Showing 1 - 50


leukemia

Anthony Moorman, PhD, on ALL: Improving Outcomes With a Tyrosine Kinase Inhibitor Plus Chemotherapy

Anthony Moorman, PhD, of Newcastle University, discusses preliminary data showing high-risk patients with acute lymphoblastic leukemia and ABL-class mutations may have improved outcomes when a tyrosine kinase inhibitor is added to chemotherapy (Abstract S117).

leukemia

Courtney D. DiNardo, MD, on AML: Venetoclax and Azacitidine for Treatment-Naive Patients

Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses data from her study of treatment-naive, predominantly older patients with acute myeloid leukemia who are ineligible for intensive therapy. The research shows venetoclax plus azacitidine improved response rates...

hepatobiliary cancer

Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGR2 Fusions

At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Javle et al reported that third- and later-line treatment with the selective fibroblast growth factor receptor (FGFR) 1–3 inhibitor infigratinib resulted in a progression-free survival and...

Expert Point of View: Toni K. Choueiri, MD

At the Genitourinary Highlights session of the ASCO20 Virtual Scientific Program, Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Boston, put these findings into perspective. “This is an important update. The initial publication was with ...

kidney cancer

Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma

Extended analysis of the phase III KEYNOTE-426 study upholds pembrolizumab plus axitinib as a preferred front-line regimen over sunitinib in patients with advanced sporadic renal cell carcinoma.1 These updated results were presented at the ASCO20 Virtual Scientific Program by Elizabeth R. Plimack,...

pancreatic cancer

Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Pancreatic Cancer Across Age Groups: Additional Analysis of the POLO Trial

According to an additional analysis from the POLO trial, safety of maintenance olaparib in patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer is consistent, irrespective of age. Patients aged ≥ 65 years derived long-term progression-free survival benefit and...

breast cancer
issues in oncology

Risk of Breast Cancer Recurrence: Serum Detection of Nonadherence to Adjuvant Tamoxifen

In a French study reported in the Journal of Clinical Oncology, Pistilli et al found that serum detection of nonadherence to adjuvant tamoxifen therapy was common and was associated with poorer distant disease-free survival among premenopausal women with breast cancer. Biochemical nonadherence was...

covid-19

A Visiting Resident Oncologist’s Training During the COVID-19 Pandemic

A visiting away elective is a resident’s designated time to visit another academic program to foster the growth of medical knowledge through patient care from the perspective of another health-care system and educational experience. The time dedicated to make this dream happen is grueling. First...

gastrointestinal cancer

Ursodeoxycholic Acid for Preventing Gallstones After Gastrectomy

In a Korean trial reported in JAMA Surgery, Lee et al found that treatment with ursodeoxycholic acid was successful in preventing gallstone formation in patients who had undergone gastrectomy for gastric cancer. Study Details In the multicenter double-blind trial, 465 evaluable patients undergoing...

bladder cancer
immunotherapy

FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma

On June 30, the U.S. Food and Drug Administration (FDA) approved avelumab (Bavencio) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy. JAVELIN Bladder 100 Efficacy of avelumab...

leukemia

Abhishek Maiti, MBBS, on AML: Decitabine and Venetoclax vs Intensive Chemotherapy

Abhishek Maiti, MBBS, of The University of Texas Health Science Center at Houston, discusses his analysis showing that 10-day decitabine and venetoclax led to superior outcomes compared with intensive chemotherapy in older patients with acute myeloid leukemia, with benefits most pronounced in...

symptom management

PICOS Score May Help Identify Patients With Brain Metastases at Risk of VTE

In a study published by Wolpert et al in the European Journal of Cancer, venous thromboembolic events (VTE) were reported in 12% of a cohort of patients with cancer that had metastasized to the brain. Researchers identified thrombogenicity of primary tumor, immobilization, chemotherapy, obesity,...

gastroesophageal cancer
issues in oncology

Study Finds Racial Disparities in Esophageal Cancer Surgical Rates

A new study published by Savitch et al in the Journal of Gastrointestinal Surgery found that black patients are less likely to receive surgery for resectable esophageal cancer, which may contribute to higher rates of death. “National guidelines suggest that early-stage esophageal cancer should be...

gynecologic cancers

Addition of an ATR Inhibitor to Gemcitabine in Platinum-Resistant High-Grade Serous Ovarian Cancer

As reported in The Lancet Oncology by Panagiotis A. Konstantinopoulos, MD, and colleagues, a phase II trial has shown significantly prolonged progression-free survival with the addition of the ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib to gemcitabine in women with...

gynecologic cancers

Meta-analysis of Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer

In a systematic review and meta-analysis of observational studies reported in JAMA Oncology, Nitecki et al found that minimally invasive radical hysterectomy was associated with increased risk of recurrence and all-cause mortality vs open surgery in women with early-stage cervical cancer. Study...

skin cancer
immunotherapy

Addition of First-Line Atezolizumab to Vemurafenib and Cobimetinib in Patients With Unresectable Advanced BRAF V600–Mutant Melanoma

As reported in The Lancet by Gutzmer et al, the phase III IMspire150 trial has shown that the addition of atezolizumab to BRAF and MEK inhibitor therapy with vemurafenib and cobimetinib improved progression-free survival in first-line treatment of patients with unresectable BRAF V600–mutant...

colorectal cancer
immunotherapy

FDA Approves Pembrolizumab for the First-Line Treatment of MSI-H/dMMR Colorectal Cancer

On June 29, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) colorectal cancer. KEYNOTE-177 Approval was based on...

breast cancer
immunotherapy

FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-Positive Breast Cancer

On June 29, the U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) for subcutaneous injection in the following indications:  Use in combination with chemotherapy as:  Neoadjuvant treatment for patients with...

multiple myeloma
immunotherapy

Parameswaran Hari, MD, on Multiple Myeloma: Expert Commentary on Four Key Abstracts

Parameswaran Hari, MD, of the Medical College of Wisconsin, discusses data from four trials and their clinical implications for the treatment of patients with multiple myeloma: the KarMMa and EVOLVE studies on CAR T cell therapies; SWOG-1211 on bortezomib, lenalidomide, and dexamthasone...

Expert Point of View: David Wise, MD and Celestia S. “Tia” Higano, MD, FACP

“GnRH antagonists have several advantages over GnRH agonists,” explained David Wise, MD, of Perlmutter Cancer Center at NYU Langone Health in New York. “There is no testosterone flare on initiation [as there is with leuprolide], no increase in cardiac toxicity, and faster onset of action. Currently ...

prostate cancer

Novel Androgen-Deprivation Therapy With Relugolix Causes Fewer Cardiac Events Than Leuprolide in Advanced Prostate Cancer

Men with prostate cancer on androgen-deprivation therapy are usually treated with leuprolide, a long-acting injectable luteinizing hormone-releasing hormone (LHRH) agonist requiring an every-3-month injection, but it may be possible for ADT to be delivered by a daily oral treatment, pending...

bladder cancer
immunotherapy

Biomarker Combination May Help Predict Response to Immunotherapy in Patients With Metastatic Urothelial Carcinoma

In patients with metastatic urothelial carcinoma, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to findings published by Goswami et al in Science...

lung cancer
covid-19

Mortality Risk in Patients With COVID-19 and Thoracic Malignancies: Initial Report From the TERAVOLT Registry Study

As reported in The Lancet Oncology by Marina C. Garassino, MD, and colleagues, initial findings from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry study have identified potential factors associated with increased risk of mortality in patients infected with COVID-19...

skin cancer

Novel Risk Calculator for Sentinel Node Positivity in Patients With Melanoma

As reported in the Journal of Clinical Oncology, Lo et al developed a novel risk calculator for sentinel node metastasis—the Melanoma Institute Australia Nomogram—that appears to more accurately predict risk of metastasis in patients with primary cutaneous melanoma than other commonly used risk...

bladder cancer
immunotherapy

Long-Term Outcomes With Pembrolizumab for Cisplatin-Ineligible Advanced Urothelial Cancer

As reported in the Journal of Clinical Oncology by Vuky et al, long-term follow-up in the phase II KEYNOTE-052 study has shown durable responses with first-line pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer, with higher response rates and longer survival in...

COVID-19 Research From the ASCO20 Virtual Scientific Program

With this week bringing record highs of COVID-19 infection across the nation, on The ASCO Post Podcast, we’re revisiting two presentations from the ASCO20 Virtual Scientific Program on the effect of the virus on patients with cancer.

lymphoma
immunotherapy

Addition of Rituximab to Standard Chemotherapy in Pediatric Patients With High-Risk, Mature B-Cell Non-Hodgkin Lymphoma

In a European Intergroup for Childhood Non-Hodgkin Lymphoma/Children’s Oncology Group phase III trial reported in The New England Journal of Medicine, Minard‑Colin et al found that the addition of rituximab to standard Lymphomes Malin B (also known as Lymphome Malin de Burkitt, or LMB) chemotherapy ...

genomics/genetics

Variant in Gene May Increase Cancer Risk in Those With Common TP53 R337H Mutations

Scientists studying a common TP53 R337H variant found among people of Brazilian descent discovered that a variant in the tumor-suppressor gene XAF1 increases cancer risk when combined with the inherited TP53 R337H mutation. These findings were published by Pinto et al in Science Advances. “We...

issues in oncology

Sedentary Behavior and Risk of Cancer Mortality

In a study that investigated objective measures of sedentary behavior and cancer mortality, researchers found that greater inactivity was independently associated with a higher risk of dying from cancer. An accelerometer was used to measure physical activity, rather than relying on participants to...

gastrointestinal cancer

Long-Term Survival Outcomes With Different Durations of Adjuvant Imatinib for Gastrointestinal Stromal Tumors

In a 10-year follow-up of the phase III SSGXVIII/AIO trial reported in JAMA Oncology, Heikki Joensuu, MD, and colleagues found that 3 years vs 1 year of adjuvant treatment with imatinib was associated with superior overall survival among patients with high-risk gastrointestinal stromal tumors. The ...

solid tumors

Effect of Radiation Boost to Residual Disease in High-Risk Neuroblastoma

In an analysis from the Children’s Oncology Group (COG) ANBL0532 study reported in the Journal of Clinical Oncology, Liu et al found that a radiotherapy boost to the gross residual tumor in patients with high-risk neuroblastoma did not appear to improve outcomes compared with patients in another...

health-care policy

Leaders of the PROMISE Study Address Racial Inequities in the United States

In 2018, researchers from Dana-Farber Cancer Institute launched a large, ambitious screening study called PROMISE (ClinicalTrials.gov identifier NCT03689595). The objectives of the study were to identify people with premalignant precursor conditions of multiple myeloma, understand the molecular...

Conquer Cancer Honors Early-Career Medical Professionals From Around the World

Conquer Cancer®, the ASCO Foundation honored recipients of the 2020 Medical Student Rotation for Underrepresented Populations (MSR), Resident Travel Awards for Underrepresented Populations (RTA), Long-Term International Fellowship (LIFe), and International Development and Education Awards (IDEA)...

Association of American Cancer Institutes Issues Statement About Racial Discrimination

In further statements from professional oncology organizations about inequities and disparities among racial and ethnic minorities and underserved populations, as well as racism and discrimination, the Association of American Cancer Institutes (AACI) issued the following statement: The AACI...

colorectal cancer

I’m Not Too Young for Colorectal Cancer

The first symptoms I had of colorectal cancer—blood in my stool and abdominal pain—coincided with surgery I had to remove my appendix in the spring of 2017. My surgeon attributed the symptoms to the appendectomy and to the medications I received both before and after the surgery. In addition to...

AMA Announces New President and President-Elect

Susan R. Bailey, MD, an allergist from Fort Worth, recently took office as the 175th President of the American Medical Association (AMA), the nation’s premier physician organization. Dr. Bailey is the third consecutive woman to hold the office, a record for the AMA. In addition, the organization...

AMA Board of Trustees Pledges Action Against Racism and Police Brutality

At a virtual Special Meeting of the American Medical Association (AMA) House of Delegates, the AMA Board of Trustees pledged action to confront systemic racism and police brutality. The AMA released the following statement that was approved at its meeting on June 5, 2020: The AMA recognizes that...

New Information From NCCN on Overcoming Challenges for People With Head and Neck Cancer

The National Comprehensive Cancer Network® (NCCN®) has now published a third book to complete the NCCN Guidelines for Patients®: Head and Neck Cancers series. Each book contains detailed, expert guidance on what to expect and management options for various cancers that impact the mouth and throat....

Melanoma Awareness: Outlook From a Young Adult

When I was 18, I was diagnosed with stage II melanoma. I had a strange spot on my back that I mentioned to my dermatologist, almost as an afterthought. It never occurred to me it could be skin cancer, let alone the most dangerous kind. I have fair skin but was by no means a sun worshipper. My...

issues in oncology

Initiate Conversations About Radiation Therapy for Bone Metastases

Although the American Society for Radiation Oncology (ASTRO) has recommended extended-fraction radiation therapy (more than 10 fractions) not be routinely used for palliation of bone metastases,1 a recently published retrospective cohort study using Medicare data for more than 12,000 patients found ...

issues in oncology

Extended-Fraction Radiation Therapy for Bone Metastases Represents Low-Value Care but Continues to Be Widely Practiced

An analysis of radiation therapy patterns among more than 12,000 Medicare patients treated for bone metastases found that 23.4% received extended-fraction radiation therapy, “wasting both health-care dollars and precious patient time,” according to the investigators.1 One-third of the treating...

An Honored Poet Explores a Lust for Life on the Boundaries of Near Death

"When the technician leaves the room, I turn my head toward the screen to interpret neoplasms, the webs of nerves, the small lit fonts in which my pathology and/or future or future end might be written. The first tumor I ever saw was a darkness on that screen, round with a long craggy finger...

Advanced Practitioner Society Issues Statement Against Systemic Racism, Discrimination

In further statements from professional oncology organizations about inequities and disparities among racial and ethnic minorities and underserved populations, as well as racism and discrimination, the Advanced Practitioner Society for Hematology and Oncology (APSHO) issued the following ...

integrative oncology

Integrating Physical Activity Into Cancer Care

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Accumulating evidence suggests the benefits of physical activity through the cancer continuum....

lung cancer

Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutation

On May 6, 2020, the oral mesenchymal-epithelial transition (MET) kinase inhibitor capmatinib was granted accelerated approval for the treatment of adult patients who have metastatic non–small cell lung cancer (NSCLC) with tumors that have a mutation that leads to MET exon 14 skipping, as detected...

integrative oncology

AIDS Research Led to Appreciation of the Power of Plants and Integrative Medicine in Cancer Care for Donald I. Abrams, MD

The path that led Donald I. Abrams, MD, to a career in oncology was a circuitous one. Although his love of science began when he was a student at Cleveland Heights High School in Ohio, and continued during college at Brown University, where he received an AB in molecular biology in 1972, he was...

NCI Renews Comprehensive Cancer Center Designation for Norris Cotton Cancer Center

The National Cancer Institute (NCI) has renewed its Cancer Center Support Grant to Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC). The 5-year, $15.5 million grant will provide continued support for NCCC’s clinical care and research missions. NCI recognized the cancer center...

Special Report Provides Guidance to Oncology Practices on Resuming Care During the COVID-19 Pandemic

As pandemic-related restrictions gradually begin to ease, oncology practices are trying to understand how to safely restore patient access to critical cancer care services. In response, ASCO released the ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemic, which...

covid-19

COVID-19 and Patients With Cancer: A Call to Action for Trainees

As oncology trainees, we develop skills to synthesize complex data and communicate this information with empathy as we accompany our patients through the trenches of a cancer diagnosis. With the current COVID-19 pandemic, an unprecedented layer of challenges has surfaced, as our patients who are...

Do You Know About ASCO’s Patient Education Materials?

ASCO Answers is a collection of oncologist-approved patient education materials developed by ASCO for people with cancer and their caregivers. ASCO Answers materials have everything your patients need to understand and manage their disease. From comprehensive guides to topic-specific booklets and...

Advertisement

Advertisement



Advertisement